Microwave-assisted preparation of paramagnetic zwitterionic amphiphilic copolymer hybrid molybdenum disulfide for T1-weighted magnetic resonance imaging-guided photothermal therapy. Issue 40 (18th September 2018)

• Record Type: Journal Article
• Authors: Yu, Yiming; Chi, Bin; Lin, Leping; Yang, Zhe; He, Qianyuan; Xu, Zushun; Yi, Changfeng; Wang, Jing
• Is Part Of: Journal of materials chemistry. Volume 6:Issue 40(2018)
• Page Start: 6391
• Page End: 6398
• Publication Date: 2018-09-18
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c8tb01660g
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Magnetic resonance imaging (MRI)-guided photothermal therapy (PTT) has recently attracted tremendous attention. Abstract : Magnetic resonance imaging (MRI)-guided photothermal therapy (PTT) has recently attracted tremendous attention. In this study, a paramagnetic zwitterionic amphiphilic copolymer (PZAC) was successfully prepared and utilized as a multifunctional surfactant to form micelles in diethylene glycol to coordinate with a molybdenum disulfide precursor (MoS2 ). Uniform spherical MoS2 nanohybrids (MoS2 @PZAC) were first prepared by a microwave-assisted solvothermal process, which is simpler, easier and more efficient than hydrothermal methods or exfoliation processes. In this nanoplatform, MoS2 serves as a phototherapeutic agent possessing a high photothermal conversion efficiency (33.8%), while PZAC acts as a T 1 -weighted MRI contrast agent. This nanoplatform has the advantages of ultralow toxicity, prolonged circulation time and bio-imaging guided capability. The cytotoxicity assessment showed the good cytocompatibility of MoS2 @PZAC. Furthermore, MoS2 @PZAC could effectively kill cancer cells upon 2 W cm −2 808 nm laser irradiation for 10 min in both in vitro and in vivo experiments. This work provides a novel and efficient solution to synthesize a multifunctional and uniform theranostic agent, and the results show that the as-prepared MoS2 @PZAC can be used as a promising theranostic agent for T 1 -weighted MRI-guided PTT of cancer cells.